What is the basis for a genetic approach in neonatal disorders?

Semin Perinatol. 2015 Dec;39(8):568-73. doi: 10.1053/j.semperi.2015.09.003. Epub 2015 Oct 23.

Abstract

Gene-environment interactions likely account for some degree of the variance in response rates that are clinically observed with antenatal corticosteroids, breast milk prophylaxis, surfactant administration, early recognition and treatment of sepsis, utility of non-invasive ventilation, and judicious exposure to supplemental oxygen. While these therapies and practice guidelines have significantly decreased overall neonatal mortality in the NICU, they have not made a marked impact on the frequency and severity of conditions such as bronchopulmonary dysplasia (BPD), necrotizing enterocolitis, and periventricular leukomalacia. One possible explanation is that genetic factors in the neonate modulate response to external intervention or preventative agents, culminating in variable levels of injury and different degrees of resolution and repair. Gene-environment explanations are supported by the observed heritability of BPD in twin studies, but they do not differentiate the interactions between neonate and offending toxin or pathogen, from interactions between neonate and intervention or therapeutic agent. Likely, both kinds of interactions are important in determining outcome.

Keywords: BPD; IVH; NEC; PDA; RDS; ROP; Twin studies; apnea of prematurity; neonatal sepsis; premature newborn.

Publication types

  • Review

MeSH terms

  • Adaptive Immunity / genetics*
  • Bronchopulmonary Dysplasia / drug therapy*
  • Bronchopulmonary Dysplasia / genetics
  • Bronchopulmonary Dysplasia / immunology
  • Enterocolitis, Necrotizing / drug therapy*
  • Enterocolitis, Necrotizing / genetics
  • Enterocolitis, Necrotizing / immunology
  • Female
  • Gene-Environment Interaction
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / adverse effects
  • Humans
  • Infant
  • Infant Mortality
  • Infant, Newborn
  • Infant, Newborn, Diseases
  • Infant, Premature
  • Intensive Care, Neonatal
  • Intermittent Positive-Pressure Ventilation
  • Male
  • Milk, Human / drug effects
  • Milk, Human / immunology*
  • Practice Guidelines as Topic
  • Pregnancy
  • Pulmonary Surfactants / administration & dosage
  • Pulmonary Surfactants / adverse effects
  • Respiratory Distress Syndrome, Newborn / drug therapy*
  • Respiratory Distress Syndrome, Newborn / genetics
  • Respiratory Distress Syndrome, Newborn / immunology
  • Retinopathy of Prematurity / drug therapy*
  • Retinopathy of Prematurity / genetics
  • Retinopathy of Prematurity / immunology
  • Sepsis / drug therapy*
  • Sepsis / immunology
  • Time Factors
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Pulmonary Surfactants

Supplementary concepts

  • Respiratory Distress Syndrome In Premature Infants